Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $20.0 million.

  • Precision Biosciences' Non-Current Deffered Revenue fell 2492.29% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year decrease of 2492.29%. This contributed to the annual value of $23.3 million for FY2024, which is 6811.8% down from last year.
  • Precision Biosciences' Non-Current Deffered Revenue amounted to $20.0 million in Q3 2025, which was down 2492.29% from $20.2 million recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Non-Current Deffered Revenue registered a high of $131.2 million during Q1 2021, and its lowest value of $20.0 million during Q3 2025.
  • In the last 5 years, Precision Biosciences' Non-Current Deffered Revenue had a median value of $73.1 million in 2023 and averaged $63.6 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 9904.91% in 2021, then crashed by 7257.98% in 2025.
  • Precision Biosciences' Non-Current Deffered Revenue (Quarter) stood at $67.0 million in 2021, then rose by 23.66% to $82.9 million in 2022, then dropped by 11.81% to $73.1 million in 2023, then plummeted by 68.12% to $23.3 million in 2024, then fell by 14.35% to $20.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $20.0 million for Q3 2025, versus $20.2 million for Q2 2025 and $20.5 million for Q1 2025.